SCHEMBL18849204

SCHEMBL18849204

CC(=O)NC1C(O)OC(CN)C(O)C1O

nearest known ligand 0.48

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.48
▸ LMNA P02545 2/20 0.46
▸ KDM4E B2RXH2 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ HK1 P19367 3/20 0.39
▸ HK2 P52789 3/20 0.39
▸ AMDHD2 Q9Y303 1/20 0.37
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ CD69 Q07108 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31105669 1.00 MAPK1 (0.48) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL28987178 0.85 MAPK1 (0.60) MAPK1LMNAKDM4ECYP2D6CYP2C19
SCHEMBL18854303 0.85 ALDH1A1 (0.42) MAPK1ALDH1A1THRBCA1CA2
N-Acetylglucosamine SCHEMBL20798032 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL24105621 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL24978032 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL25229254 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL20842453 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL22748805 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19
N-Acetylglucosamine SCHEMBL20621758 0.84 MAPK1 (0.63) MAPK1LMNAKDM4ECYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988661-B2 Process for the modification of a glycoprotein using a glycosyltransferase that is or is derived from A β(1,4)-N-acetylgalactosaminyltransferase SYNAFFIX B.V. (NL) 2018-06-05 — — US disclosed
US-20170130256-A1 PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A ß(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE SYNAFFIX B.V. (NL) 2017-05-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170130256-A1 PROCESS FOR THE MODIFICATION OF A GLYCOPROTEIN USING A GLYCOSYLTRANSFERASE THAT IS OR IS DERIVED FROM A ß(1,4)-N-ACETYLGALACTOSAMINYLTRANSFERASE CSGALNACT1, B4GALT1, FUT8 MAPK1 3260/4885LMNA 3919/4885KDM4E 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback